1. Market Research
  2. > Glioma – Pipeline Review, H1 2013

Glioma – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 568 pages

Glioma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glioma.
- A review of the Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glioma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glioma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Glioma - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
Introduction 7
Glioma Overview 8
Therapeutics Development 9
Glioma Therapeutics under Development by Companies 11
Glioma Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 25
Mid Clinical Stage Products 26
Early Clinical Stage Products 27
Discovery and Pre-Clinical Stage Products 28
Glioma Therapeutics - Products under Development by Companies 29
Glioma Therapeutics - Products under Investigation by Universities/Institutes 40
Companies Involved in Glioma Therapeutics Development 44
Glioma - Therapeutics Assessment 150
Drug Profiles 158
Glioma Therapeutics - Drug Profile Updates 444
Glioma Therapeutics - Discontinued Products 526
Glioma Therapeutics - Dormant Products 528
Glioma - Product Development Milestones 538
Appendix 548



List of Tables

Number of Products Under Development for Glioma, H1 2013 28
Products under Development for Glioma - Comparative Analysis, H1 2013 29
Number of Products under Development by Companies, H1 2013 31
Number of Products under Development by Companies, H1 2013 (Contd..1) 32
Number of Products under Development by Companies, H1 2013 (Contd..2) 33
Number of Products under Development by Companies, H1 2013 (Contd..3) 34
Number of Products under Development by Companies, H1 2013 (Contd..4) 35
Number of Products under Development by Companies, H1 2013 (Contd..5) 36
Number of Products under Development by Companies, H1 2013 (Contd..6) 37
Number of Products under Development by Companies, H1 2013 (Contd..7) 38
Number of Products under Development by Companies, H1 2013 (Contd..8) 39
Number of Products under Investigation by Universities/Institutes, H1 2013 41
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 42
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 43
Comparative Analysis by Late Stage Development, H1 2013 44
Comparative Analysis by Mid Clinical Stage Development, H1 2013 45
Comparative Analysis by Early Clinical Stage Development, H1 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 47
Products under Development by Companies, H1 2013 48
Products under Development by Companies, H1 2013 (Contd..1) 49
Products under Development by Companies, H1 2013 (Contd..2) 50
Products under Development by Companies, H1 2013 (Contd..3) 51
Products under Development by Companies, H1 2013 (Contd..4) 52
Products under Development by Companies, H1 2013 (Contd..5) 53
Products under Development by Companies, H1 2013 (Contd..6) 54
Products under Development by Companies, H1 2013 (Contd..7) 55
Products under Development by Companies, H1 2013 (Contd..8) 56
Products under Development by Companies, H1 2013 (Contd..9) 57
Products under Development by Companies, H1 2013 (Contd..10) 58
Products under Investigation by Universities/Institutes, H1 2013 59
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 60
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 61
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 62
Bristol-Myers Squibb Company, H1 2013 63
Boehringer Ingelheim GmbH, H1 2013 64
F. Hoffmann-La Roche Ltd., H1 2013 65
Vical Incorporated, H1 2013 66
Amgen Inc., H1 2013 67
Sanofi-Aventis, H1 2013 68
AstraZeneca PLC, H1 2013 69
Eli Lilly and Company, H1 2013 70
Viralytics Ltd., H1 2013 71
Genentech, Inc., H1 2013 72
Nektar Therapeutics, H1 2013 73
Antigenics, Inc., H1 2013 74
MedImmune LLC, H1 2013 75
Gilead Sciences, Inc., H1 2013 76
Lentigen Corporation, H1 2013 77
Sangamo BioSciences, Inc., H1 2013 78
Plexxikon Inc., H1 2013 79
Celltrion, Inc., H1 2013 80
Histogen, Inc., H1 2013 81
Novartis AG, H1 2013 82
Actelion Ltd, H1 2013 83
Astellas Pharma Inc., H1 2013 84
Nippon Shinyaku Co., Ltd., H1 2013 86
Pfizer Inc., H1 2013 87
Teva Pharmaceutical Industries Limited, H1 2013 88
Cell Therapeutics, Inc., H1 2013 89
Exelixis, Inc., H1 2013 90
Aduro BioTech, H1 2013 91
Alfacell Corporation, H1 2013 92
EpiCept Corporation, H1 2013 93
GW Pharmaceuticals plc, H1 2013 94
Celldex Therapeutics, Inc., H1 2013 95
AEterna Zentaris Inc., H1 2013 96
ImmunoCellular Therapeutics, Ltd., H1 2013 97
Lixte Biotechnology Holdings, Inc., H1 2013 98
Basilea Pharmaceutica Ltd., H1 2013 99
Northwest Biotherapeutics, Inc., H1 2013 100
Novogen Limited, H1 2013 101
Cleveland BioLabs, Inc., H1 2013 102
Oncothyreon Inc, H1 2013 103
Peregrine Pharmaceuticals, Inc., H1 2013 104
Telik, Inc., H1 2013 105
Cytomedix, Inc., H1 2013 106
Transgene SA, H1 2013 107
Prana Biotechnology Limited, H1 2013 108
Innocell Corporation, H1 2013 109
Diamyd Medical AB, H1 2013 110
Threshold Pharmaceuticals, Inc., H1 2013 111
Natco Pharma Limited, H1 2013 112
Proximagen Neuroscience plc., H1 2013 113
e-Therapeutics plc, H1 2013 114
Rexahn Pharmaceuticals, Inc., H1 2013 115
Nanobiotix, H1 2013 116
Spectrum Pharmaceuticals, Inc., H1 2013 117
Colby Pharmaceutical Company, H1 2013 118
INSYS Therapeutics, Inc., H1 2013 119
Ambit Biosciences Corporation, H1 2013 120
Nerviano Medical Sciences S.r.l., H1 2013 122
immatics biotechnologies GmbH, H1 2013 123
Advantagene, Inc., H1 2013 124
Apogenix GmbH, H1 2013 125
EnGeneIC Ltd, H1 2013 126
AGY Therapeutics, Inc., H1 2013 127
Hawthorn Pharmaceuticals, Inc., H1 2013 128
Diffusion Pharmaceuticals LLC, H1 2013 129
MacroGenics, Inc., H1 2013 130
Fina Biotech, H1 2013 131
Arno Therapeutics, Inc., H1 2013 132
Merrimack Pharmaceuticals, Inc., H1 2013 133
Deciphera Pharmaceuticals, LLC, H1 2013 134
Vascular Biogenics Ltd., H1 2013 135
Burzynski Research Institute, Inc., H1 2013 136
Stemline Therapeutics, Inc., H1 2013 137
BioCancell Therapeutics, Inc., H1 2013 138
Advenchen Laboratories, LLC, H1 2013 140
Viral Genetics, Inc., H1 2013 141
NOXXON Pharma AG, H1 2013 142
Globeimmune, Inc., H1 2013 143
ChemoCentryx, Inc., H1 2013 144
TVAX Biomedical, LLC, H1 2013 145
Biovista Inc., H1 2013 146
Sirnaomics, Inc., H1 2013 147
Targepeutics, Inc., H1 2013 149
Lipopharma, H1 2013 150
Kringle Pharma, Inc., H1 2013 151
Oncovir, Inc., H1 2013 152
TRACON Pharmaceuticals, Inc., H1 2013 153
Nexgenix Pharmaceuticals, LLC, H1 2013 154
Regulus Therapeutics Inc., H1 2013 155
Galaxy Biotech, LLC, H1 2013 156
Lee's Pharmaceutical Holdings Limited, H1 2013 157
DiscoveryBiomed, Inc., H1 2013 158
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2013 159
n.v. BRUCELLS s.a., H1 2013 160
GreenPeptide Co., Ltd., H1 2013 161
PepTx, Inc., H1 2013 162
TAU Therapeutics, LLC, H1 2013 163
EirGen Pharma Ltd., H1 2013 164
CytoVac A/S, H1 2013 165
Ampio Pharmaceuticals, Inc., H1 2013 167
CytomX, LLC., H1 2013 168
Assessment by Monotherapy Products, H1 2013 169
Assessment by Combination Products, H1 2013 170
Assessment by Stage and Route of Administration, H1 2013 173
Assessment by Stage and Molecule Type, H1 2013 176
Glioma Therapeutics - Drug Profile Updates 463
Glioma Therapeutics - Discontinued Products 545
Glioma Therapeutics - Discontinued Products (Contd..1) 546
Glioma Therapeutics - Dormant Products 547
Glioma Therapeutics - Dormant Products (Contd..1) 548
Glioma Therapeutics - Dormant Products (Contd..2) 549
Glioma Therapeutics - Dormant Products (Contd..3) 550
Glioma Therapeutics - Dormant Products (Contd..4) 551
Glioma Therapeutics - Dormant Products (Contd..5) 552
Glioma Therapeutics - Dormant Products (Contd..6) 553
Glioma Therapeutics - Dormant Products (Contd..7) 554
Glioma Therapeutics - Dormant Products (Contd..8) 555
Glioma Therapeutics - Dormant Products (Contd..9) 556



List of Figures

Number of Products under Development for Glioma, H1 2013 28
Products under Development for Glioma - Comparative Analysis, H1 2013 29
Products under Development by Companies, H1 2013 30
Products under Investigation by Universities/Institutes, H1 2013 40
Late Stage Products, H1 2013 44
Mid Clinical Stage Products, H1 2013 45
Early Clinical Stage Products, H1 2013 46
Discovery and Pre-Clinical Stage Products, H1 2013 47
Assessment by Monotherapy Products, H1 2013 169
Assessment by Combination Products, H1 2013 170
Assessment by Route of Administration, H1 2013 171
Assessment by Stage and Route of Administration, H1 2013 172
Assessment by Molecule Type, H1 2013 174
Assessment by Stage and Molecule Type, H1 2013 175

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.